Irwin Naturals Expands Operations into Northeast with Acquisition of Vermont-Based Clinic
June 17, 2022
Ryan Allway June 17th, 2022 News, Top News Company continues national growth trajectory for Emergence clinics focusing on total wellness including the therapeutic use of ketamine LOS ANGELES, June 17, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has entered... Read more
Ryan Allway June 3rd, 2022 News, Top News TORONTO, June 3, 2022 /CNW/ – TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter” or the “Company”), today announced the official launch of the TripSitter App, a simple and free App that makes it easy for users to access TripSitter Clinics’ services. TripSitter.Clinic Launches... Read more
Company Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics
April 18, 2022
Ryan Allway April 18th, 2022 Psychedelics, Top News LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has taken the next step in the execution of its ketamine clinic roll-up strategy – a move the Company... Read more
Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine Clinic
March 29, 2022
Ryan Allway March 29th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 29, 2022–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (“Merger Agreement“) to acquire Alchemy Wellness (“Alchemy“) a... Read more
Ryan Allway January 28th, 2022 Psychedelics, Top Story Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through... Read more
NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board
January 13, 2022
Ryan Allway January 13th, 2022 Psychedelics Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, announced... Read more
Revitalist Increases Clinic Count to Nine With Closing of Florida Clinic Acquisition
January 12, 2022
Ryan Allway January 12th, 2022 Psychedelics, Top News REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that it has executed an asset purchase agreement (“Agreement”) dated January 11, 2022, to acquire a Ketamine clinic located in Jacksonville, Florida... Read more
Ryan Allway December 10th, 2021 Psychedelics, Top Story Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq.... Read more
Awakn Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry
November 4, 2021
Ryan Allway November 4th, 2021 Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that the ‘Ketamine in the Reduction of Alcoholic... Read more
Silo Pharma’s Sponsored Research Agreement with Columbia Could Yield a New Alzheimer’s Disease Treatment
November 3, 2021
Ryan Allway November 3rd, 2021 Psychedelics, Top Story Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet,... Read more
